{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:33Z","timestamp":1793041953736,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T00:00:00Z","timestamp":1504656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T00:00:00Z","timestamp":1504656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR\u2009+\u2009HER2- metastatic breast cancer patients treated with everolimus-exemestane in first and subsequent lines. Best overall response (BR) and clinical benefit rate (CBR) were assessed across subgroups defined upon fasting glucose (FG) and body mass index (BMI). Survival was estimated by Kaplan-Meier method and log-rank test. Survival predictors were tested in Cox models. Median follow up was 12.4 months (1.0\u201341.0). The overall cohort showed increasing levels of FG and decreasing BMI (p\u2009&lt;\u20090.001). Lower FG fasting glucose at BR was more commonly associated with C\/PR or SD compared with PD (p\u2009&lt;\u20090.001). We also observed a somewhat higher BMI associated with better response (p\u2009=\u20090.052). More patients in the lowest FG category achieved clinical benefit compared to the highest (p\u2009&lt;\u20090.001), while no relevant differences emerged for BMI. Fasting glucose at re-assessment was also predictive of PFS (p\u2009=\u20090.037), as confirmed in models including BMI and line of therapy (p\u2009=\u20090.049). Treatment discontinuation was significantly associated with changes in FG (p\u2009=\u20090.014). Further research is warranted to corroborate these findings and clarify the underlying mechanisms.<\/jats:p>","DOI":"10.1038\/s41598-017-10061-2","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T07:29:26Z","timestamp":1504164566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study"],"prefix":"10.1038","volume":"7","author":[{"given":"Laura","family":"Pizzuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Natoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Gamucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Fedele","family":"Scinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Mentuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Botticelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Moscetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sperati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ferranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Buglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sanguineti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"di Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Sergi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Catenaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silverio","family":"Tomao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Maugeri-Sacc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9050-2917","authenticated-orcid":false,"given":"Maddalena","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Vici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,6]]},"reference":[{"key":"10061_CR1","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. \n                           366, 520\u2013529 (2012).","journal-title":"N Engl J Med."},{"key":"10061_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.clbc.2013.08.011","volume":"13","author":"KI Pritchard","year":"2013","unstructured":"Pritchard, K. I. et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer. \n                           13, 421\u2013432 (2013).","journal-title":"Clin Breast Cancer."},{"key":"10061_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s12282-013-0444-8","volume":"21","author":"S Noguchi","year":"2014","unstructured":"Noguchi, S. et al. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer. \n                           21, 703\u201314 (2014).","journal-title":"Breast Cancer."},{"key":"10061_CR4","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley, D. A. et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. \n                           30, 870\u201384 (2013).","journal-title":"Adv Ther."},{"key":"10061_CR5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/annonc\/mdu009","volume":"25","author":"HS Rugo","year":"2014","unstructured":"Rugo, H. S. et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol. \n                           25, 808\u201315 (2014).","journal-title":"Ann Oncol."},{"key":"10061_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1158\/1055-9965.EPI-08-0808","volume":"18","author":"S Sieri","year":"2009","unstructured":"Sieri, S. et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev. \n                           18, 169\u2013176 (2009).","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10061_CR7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/jnci\/djg022","volume":"95","author":"TJ Key","year":"2003","unstructured":"Key, T. J. et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. \n                           95, 1218\u20131262 (2003).","journal-title":"J Natl Cancer Inst."},{"key":"10061_CR8","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1016\/j.ejca.2013.08.004","volume":"49","author":"P Minicozzi","year":"2013","unstructured":"Minicozzi, P. et al. High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease. Eur J Cancer. \n                           49, 3881\u20138 (2013).","journal-title":"Eur J Cancer."},{"key":"10061_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116527","volume":"20","author":"J Feliu","year":"2015","unstructured":"Feliu, J. et al. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS One. \n                           20, e0116527 (2015).","journal-title":"PLoS One."},{"key":"10061_CR10","doi-asserted-by":"crossref","unstructured":"Tappenden, P., Jone, R., Paisley, S., Carroll, C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer Health Technol Assess. 11, 1\u2013128, iii-iv (2007).","DOI":"10.3310\/hta11120"},{"key":"10061_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.5456","volume":"27","author":"A Vazquez-Martin","year":"2009","unstructured":"Vazquez-Martin, A., Oliveras-Ferraros, C., Del Barco, S., Martin-Castillo, B. & Menendez, J. A. If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like receptor I axis will audit the efficacy of metformin in clinical trials. J Clini Oncol. \n                           27, e207 (2009).","journal-title":"J Clini Oncol."},{"key":"10061_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.breast.2016.07.005","volume":"28","author":"L Moscetti","year":"2016","unstructured":"Moscetti, L. et al. Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience. Breast. \n                           28, 96\u2013101 (2016).","journal-title":"Breast."},{"key":"10061_CR13","unstructured":"American Diabetes Association 2012. Hyperglycemia and Diabetes, Available at: http:\/\/www.medicinenet.com\/."},{"key":"10061_CR14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ejca.2013.11.022","volume":"50","author":"A Ravaud","year":"2014","unstructured":"Ravaud, A. et al. Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology. Eur J Cancer. \n                           50, 486\u201395 (2014).","journal-title":"Eur J Cancer."},{"key":"10061_CR15","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.ejca.2012.03.012","volume":"48","author":"DA Dabydeen","year":"2012","unstructured":"Dabydeen, D. A. et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer \n                           48, 1519\u201324 (2012).","journal-title":"Eur J Cancer"},{"key":"10061_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/bju.12420","volume":"113","author":"BJ Atkinson","year":"2014","unstructured":"Atkinson, B. J. et al. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int. \n                           113, 376\u201382 (2014).","journal-title":"BJU Int."},{"key":"10061_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120427","volume":"10","author":"F Pantano","year":"2015","unstructured":"Pantano, F. et al. The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker? PLoS One. \n                           10, e0120427 (2015).","journal-title":"PLoS One."},{"key":"10061_CR18","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/j.1553-2712.2005.tb00968.x","volume":"12","author":"JT Nagurney","year":"2005","unstructured":"Nagurney, J. T. et al. The accuracy and completeness of data collected by prospective and retrospective methods. Acad Emerg Med. \n                           12, 884\u201395 (2005).","journal-title":"Acad Emerg Med."},{"key":"10061_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1553-2712.2004.tb01433.x","volume":"11","author":"A Worster","year":"2004","unstructured":"Worster, A. & Haines, T. Advanced statistics: understanding medical record review (MRR) studies. Acad Emerg Med. \n                           11, 187\u201392 (2004).","journal-title":"Acad Emerg Med."},{"key":"10061_CR20","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1093\/annonc\/mdr540","volume":"23","author":"M Barba","year":"2012","unstructured":"Barba, M. et al. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from historic cohort. Ann Oncol. \n                           23, 1838\u201345 (2012).","journal-title":"Ann Oncol."},{"key":"10061_CR21","doi-asserted-by":"publisher","first-page":"10382","DOI":"10.18632\/oncotarget.2060","volume":"5","author":"P Vici","year":"2014","unstructured":"Vici, P. et al. p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. Oncotarget. \n                           5, 10382\u201392 (2014).","journal-title":"Oncotarget."},{"key":"10061_CR22","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/jcp.24891","volume":"230","author":"P Vici","year":"2014","unstructured":"Vici, P. et al. Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer. J Cell Physiol. \n                           230, 1708\u201312 (2014).","journal-title":"J Cell Physiol."},{"key":"10061_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.7150\/jca.13578","volume":"7","author":"P Vici","year":"2016","unstructured":"Vici, P. et al. Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. J Cancer. \n                           7, 516\u201322 (2016).","journal-title":"J Cancer."},{"key":"10061_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000405017","volume":"10","author":"K Almstedt","year":"2015","unstructured":"Almstedt, K. & Schmidt, M. Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Breast Care (Basel). \n                           10, 168\u201372 (2015).","journal-title":"Breast Care (Basel)."},{"key":"10061_CR25","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1038\/onc.2014.328","volume":"34","author":"LM Dillon","year":"2015","unstructured":"Dillon, L. M. et al. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K\/AKT and MEK\/ERK signaling in breast cancer. Oncogene. \n                           34, 3968\u201376 (2015).","journal-title":"Oncogene."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10061-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10061-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10061-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T10:16:44Z","timestamp":1671790604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10061-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["10061"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-10061-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,6]]},"assertion":[{"value":"3 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10597"}}